tirzepatide and hormones FDA approval for Zepbound (tirzepatide) injection, the first only obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors - Eli Lilly What Makes Tirzepatide Different? Inside

The Preclinical Foundation Before human clinical trials began, the case for GLP-1 agonists in addiction was built on a robust body of animal research spanning more than a decade

In addition, manufacturers need to establish a product traceability system to ensure that products can be recalled promptly when quality problems occur

Medication Mechanism of Action Average Weight Loss Retatrutide Triple agonist (GLP-1, GIP, Glucagon) Up to 24% average weight loss over 48 weeks Semaglutide GLP-1 receptor agonist Up to 17% over 68 weeks Tirzepatide Dual agonist (GLP-1, GIP) Up to 25% over 52 weeks Retatrutide is used to help with weight loss

Individuals need to weigh risks and benefits